CNST - コンステレ―ション・ファ―マシュ―ティカルズ (Constellation Pharmaceuticals Inc.) コンステレ―ション・ファ―マシュ―ティカルズ



symbol CNST
会社名 Constellation Pharmaceuticals Inc (コンステレ―ション・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Constellation Pharmaceuticals Inc. is a United States-based company which discovers and develops small molecule therapeutics for the treatment of cancer inflammatory/immunologic disorders and other diseases. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound CPI-0610 and the other program is evaluating a compound CPI-1205. CPI-0610 is a small molecule that inhibits the binding of bromodomain and extra terminal (BET) proteins to chromatin. CPI-1205 is a small molecule that inhibits an enzyme Enhancer of Zeste Homolog 2 (EZH2). It is in a Phase I clinical study of CPI-0610 in patients with progressive lymphoma; a Phase I clinical study of CPI-0610 in patients with acute leukemia myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms; a Phase I clinical study of CPI-0610 in patients with previously treated multiple myeloma and a Phase 1 clinical study of CPI-1205 in patients with lymphoma.   コンステレ―ション・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、異常な遺伝子発現や薬剤耐性に起因するがん患者の治療薬の開発に従事する。同社の医薬品候補CPI-1205は、アンドロゲン受容体シグナル伝達阻害剤と組み合わせた前立腺がんの治療、免疫と組み合わせた固形がんの治療に使用される。本社所在地はマサチュ―セッツ州ケンブリッジ。   Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.
本社所在地 215 First Street Suite 200 Cambridge MA 02142 USA
代表者氏名 Mark A. Goldsmith マークA.ゴールドスミス
代表者役職名 Executive Chairman Venture Partner
電話番号 +1 617-714-0555
設立年月日 39448
市場名 NASDAQ National Market System
ipoyear 2018年
EBITDA EBITDA(百万ドル) -45.22600
終値(lastsale) 6.78
時価総額(marketcap) 174373667.4
時価総額 時価総額(百万ドル) 174.88800
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 360.13900
当期純利益 当期純利益(百万ドル) -55.62300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Constellation Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 8% to $24M. Higher net loss reflects FV Adjustments of Financial Investments decrease from $4.4M (income) to $0K Research and development - Balancing increase of 29% to $18.9M (expense) General and administrative - Balanci increase of 66% to $2.3M (expense).



   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug  2019/12/04 12:06:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Ardelyx Inc (NASDAQ: ARDX )(announced positive results for the Phase 3 study of tenapanor as monotherapy for treating hyperphosphatemia in patients with chronic kidney disease on dialysis) Audentes Therapeutics Inc (NASDAQ: BOLD )( announced a deal to be bought by ASTELLAS PHARMA/ADR (OTC: ALPMY )) Axsome Therapeutics Inc (NASDAQ: AXSM )(announced positive mid-stage readout for drug to treat narcolepsy) Cassava Sciences Inc (NASDAQ: SAVA ) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Inspire Medical Systems Inc (NYSE: INSP ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Recro Pharma Inc (NASDAQ: REPH ) Xenon Pharmaceuticals Inc (NASDAQ: XENE ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 3) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Evelo Biosciences Inc (NASDAQ: EVLO ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Neon Therapeutics Inc (NASDAQ: NTGN ) Orgenesis Inc (NASDAQ: ORGS ) Predictive Oncology Inc (NASDAQ: POAI ) Protagonist Therapeutics Inc (NASDAQ: PTGX )(announced results from mid-stage study of PTG-300 in transfusion-dependent beta-thalassemia) Therapix Biosciences …
   CNST Stock Is Particularly Risky After Its Recent Run  2019/11/18 11:40:01 InvestorPlace
Undoubtedly, Constellation Pharmaceuticals stock is one of the hottest names right now on Wall Street, but caution here is key.
   The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs  2019/11/07 10:38:02 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Constellation Pharmaceuticals Inc (NASDAQ: CNST )(announced positive results from a Phase 2 trial of CPI-0610 in combination with Jakafi in myelofibrosis) Exagen Inc (NASDAQ: XGN ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Viela Bio Inc (NASDAQ: VIE ) (IPOed Oct. 3) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 6) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Biocept Inc (NASDAQ: BIOC ) bluebird bio Inc (NASDAQ: BLUE ) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Exelixis, Inc.
   Constellation Pharma Skyrockets More Than 100% on Promising Drug Trial Data  2019/11/06 16:48:00
   First Quarter U.S. Equity Market Recap  2019-04-03
Below is a snapshot of total returns across asset classes using key ETFs traded on US exchanges. For each ETF, we show its total return over the last 12 months, year-to-date through Q1, and in March. In the US, smallcap ETFs like [[IJR]] and [[IWM]] lagged badly in March, and they're only up…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンステレ―ション・ファ―マシュ―ティカルズ CNST Constellation Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)